高危人群植入式心脏监测器检出既往未诊断房颤的发病率:REVEAL AF研究
REVEAL AF是一项前瞻性单臂多中心研究,纳入CHADS2评分≥3(或2且至少1个额外危险因素)的患者,植入式心脏监测器监测18-30个月。主要终点为18个月时持续≥6分钟的房颤检出率,结果为29.3%;30天检出率仅6.2%,提示延长监测可显著提高检出。
要点
- 高危患者植入式监测18个月房颤检出率达29.3%。
- 仅监测30天会漏诊多数房颤,检出率仅6.2%。
- 检出房颤后56.3%的患者启动口服抗凝治疗。
核心结论
- 在有房颤和卒中危险因素的患者中,既往未诊断的房颤发生率可能较高。
- 若监测仅限于30天,大多数患者的房颤将不会被发现。
- 需要进一步试验评估检测亚临床房颤和预防性治疗的价值。
研究设计与样本
- 纳入CHADS2评分≥3(或2且至少1个额外危险因素)的患者,约90%有非特异性症状可能符合房颤。
- 共446例患者入组,平均(SD)年龄71.5(9.9)岁,233例(52.2%)为男性。
- 385例(86.3%)接受植入式心脏监测器并符合主要分析队列,平均(SD)观察22.5(7.7)个月。
主要发现
- 18个月时持续≥6分钟的房颤检出率为29.3%。
- 30天、6、12、24和30个月的检出率分别为6.2%、20.4%、27.1%、33.6%和40.0%。
- 从设备植入到首次检出房颤的中位(四分位距)时间为123(41-330)天。
- 达到主要终点的患者中,13例(10.2%)有至少1次持续≥24小时的发作,72例(56.3%)接受了口服抗凝治疗。
临床怎么用
- 对于有房颤和卒中危险因素的高危患者,可考虑使用植入式心脏监测器进行延长监测以提高房颤检出。
- 不应仅依赖30天监测来排除房颤,因其漏诊率较高。
局限性
- 单臂设计,无对照组。
- 约90%患者有非特异性症状,可能影响结果外推。
- 部分患者未接受监测器或未完成主要分析队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In approximately 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF. OBJECTIVE: To quantify the incidence of AF in patients at high risk for but without previously known AF using an insertable cardiac monitor. DESIGN, SETTING, AND PARTICIPANTS: This prospective, single-arm, multicenter study was conducted from November 2012 to January 2017. Visits took place at 57 centers in the United States and Europe. Patients with a CHADS2 score of 3 or greater (or 2 with at least 1 additional risk factor) were enrolled. Approximately 90% had nonspecific symptoms potentially compatible with AF, such as fatigue, dyspnea, and/or palpitations. EXPOSURES: Patients underwent monitoring with an insertable cardiac monitor for 18 to 30 months. MAIN OUTCOMES AND MEASURES: The primary end point was adjudicated AF lasting 6 or more minutes and was assessed at 18 months. Other analyses included detection rates at points from 30 days to 30 months and among CHADS2 score subgroups. Median time from insertion to detection and the percentage of patients subsequently prescribed oral anticoagulation therapy was also determined. RESULTS: A total of 446 patients were enrolled; 233 (52.2%) were male, and the mean (SD) age was 71.5 (9.9) years. A total of 385 patients (86.3%) received an insertable cardiac monitor, met the primary analysis cohort definition, and were observed for a mean (SD) period of 22.5 (7.7) months. The detection rate of AF lasting 6 or more minutes at 18 months was 29.3%. Detection rates at 30 days and 6, 12, 24, and 30 months were 6.2%, 20.4%, 27.1%, 33.6%, and 40.0%, respectively. At 18 months, AF incidence was similar among patients with CHADS2 scores of 2 (24.7%; 95% CI, 17.3-31.4), 3 (32.7%; 95% CI, 23.8-40.7), and 4 or greater (31.7%; 95% CI, 22.0-40.3) (P = .23). Median (interquartile) time from device insertion to first AF episode detection was 123 (41-330) days. Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (56.3%). CONCLUSIONS AND RELEVANCE: The incidence of previously undiagnosed AF may be substantial in patients with risk factors for AF and stroke. Atrial fibrillation would have gone undetected in most patients had monitoring been limited to 30 days. Further trials regarding the value of detecting subclinical AF and of prophylactic therapies are warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01727297.
引用
- Reiffel JA, Verma A, Kowey PR, et al. Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. JAMA Cardiol. 2017. PMID: 28842973. doi:10.1001/jamacardio.2017.3180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。